Hours after Pfizer and BioNtech won the support of an FDA team for the MRNA vaccine, Sanofi and GSK announced that their meticulously developed plan to develop a vaccine to fight Govt-19 had suffered a major setback. Companies announced early Friday that they were delaying a development program for the reconstituted protein-based Covit-19 vaccine because the study failed among adults over 49 years of age. The researchers noted that “the immune response in the elderly is low due to insufficient concentration of antigen”. The collaborators, who had hoped to start the third phase this month, are now planning a second phase study of the modified vaccine with enhanced antigen development. That 2-shot study is scheduled to begin in February, which compares to a vaccine installed on the market. The move will force H1N1 to delay vaccine delivery from H1N1 to the 4th quarter of 2021, following expectations that some officials in Operation Warp Speed may see an end to the epidemic in the United States. GSK and Sanofi predict that hundreds of millions of doses of this vaccine will be brought out of global markets, representing the vast majority of vaccine quantities that the world needs to fight the epidemic. The companies signed an agreement to work with the WHO to distribute their vaccine equally, which gave hope that a vaccine would be available in the least privileged countries in the world. Their vaccine required a slow approach to development, but many used what they believed to be the most reliable technology to deliver the vaccine worldwide. Now, Pfizer / Bioendech and Moderna are gaining acceptance because AstroGeneca faces questions about the low performance found in its later stage study. Any such setback threatens to extend the time it takes to eradicate the virus, as the first approved vaccines may be in short supply for some time. This will accelerate the virtual revolution that is now taking place in the vaccine industry because traditional technology is leading to a faster and more transparent MRNA approach. Sanofi and GSK, two of the world’s leading vaccine makers, have stayed in the race even though they have fallen well behind the leaders. Thomas Triumph “We have identified the way forward and are confident and determined to bring the safe and effective COVID-19 vaccine. Following these results and new encouraging new advance data, we will now work to further develop our candidate to achieve this goal, ”said Thomas Triumbe, Executive Vice President and Chairman of Sanofi Pastor. “No pharmaceutical company can develop this alone; the world needs more than one vaccine to fight the infection.” To see all End Points News Corona virus stories, check out our special news channel.